HPV types and disease burden of anal cancer in China
Understanding the Human Papillomavirus Genotype Attribution and Disease Burden of Anal Cancer in China: A Multicenter Hospital-based Study
This project will test which HPV types are found in people with anal cancer in China and describe who is affected.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06670495 on ClinicalTrials.gov |
What this trial studies
This observational study will collect tumor specimens and clinical and demographic data from patients diagnosed with anal cancer at Fudan University Shanghai Cancer Center. Tumor samples will be tested for presence and genotype of human papillomavirus (HPV) to determine the distribution of HPV types in anal cancer. The study will also describe epidemiological characteristics, temporal trends, and the overall disease burden of anal cancer in China. Patients with HIV infection, post‑transplant immunosuppression, or who received radiation or chemotherapy before specimen collection are excluded.
Who should consider this trial
Good fit: Adults diagnosed with anal cancer in China who have not had radiation or chemotherapy before specimen collection and who consent to provide tumor specimens are ideal candidates.
Not a fit: People with HIV, those with post‑transplant immunosuppression, patients who already received chemo/radiation before specimen collection, or cases without available specimens are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could guide prevention and screening strategies and inform HPV vaccination and public health policy for anal cancer in China.
How similar studies have performed: International studies have established a strong link between HPV and anal cancer and characterized genotypes elsewhere, but large-scale genotype and burden data specifically from China are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Patients diagnosed with anal cancers, (2) Patients without radiation or chemotherapy prior to specimen collection; Exclusion Criteria: * (1) Patients with HIV infection, (2) Patients with immunosuppression after solid organ transplantation, (3) Those who do not agree to specimen collection and testing, (4) For retrospective study cases, those who without specimen.
Where this trial is running
Shanghai
- Fudan University Shanghai Cancer Center — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Ying Zheng
- Email: zhengying@fudan.edu.cn
- Phone: 86-21-64175590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.